Heartland Advisors Inc. Cuts Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Heartland Advisors Inc. lowered its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 27.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 300,567 shares of the medical equipment provider’s stock after selling 112,426 shares during the quarter. Heartland Advisors Inc. owned 0.07% of Smith & Nephew SNATS worth $9,862,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Cary Street Partners Financial LLC increased its position in shares of Smith & Nephew SNATS by 1.8% during the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after acquiring an additional 365 shares during the period. Vise Technologies Inc. increased its position in shares of Smith & Nephew SNATS by 4.7% during the third quarter. Vise Technologies Inc. now owns 9,642 shares of the medical equipment provider’s stock worth $350,000 after acquiring an additional 437 shares during the period. Quadrant Capital Group LLC increased its position in shares of Smith & Nephew SNATS by 3.6% during the third quarter. Quadrant Capital Group LLC now owns 12,757 shares of the medical equipment provider’s stock worth $463,000 after acquiring an additional 440 shares during the period. First Trust Advisors LP increased its position in shares of Smith & Nephew SNATS by 4.6% during the third quarter. First Trust Advisors LP now owns 10,532 shares of the medical equipment provider’s stock worth $382,000 after acquiring an additional 459 shares during the period. Finally, Huntington National Bank increased its position in shares of Smith & Nephew SNATS by 36.4% during the fourth quarter. Huntington National Bank now owns 1,928 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 514 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SNN. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a research report on Monday, May 11th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Canaccord Genuity Group cut their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Smith & Nephew SNATS currently has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Trading Down 1.1%

NYSE:SNN opened at $30.96 on Thursday. The business’s fifty day moving average price is $31.35 and its 200 day moving average price is $32.86. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. Smith & Nephew SNATS, Inc. has a 12 month low of $28.40 and a 12 month high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last posted its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The business had revenue of $1.60 billion during the quarter. Analysts anticipate that Smith & Nephew SNATS, Inc. will post 2.25 earnings per share for the current fiscal year.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.